ArticleScientific reports2026
Artificial intelligence with deep convolutional neural network-based clinical decision-making on kidney Oncology using multimodal imaging.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney cancer is among the most prevalent malignancies globally. Accurate analysis is vital in managing kidney cancer patients affected by tumour volume or size, cancer stages, and types. This results in a massive quantity of medical data on every patient, like histopathological images, magnetic resonance imaging (MRI) or computed tomography (CT) scans, and other clinical information. In recent times, automatic analysis of kidney cancer has been a significant task, particularly when utilizing deep learning (DL), owing to the import of training medicinal data are demanding and costly to acquire. Unlike preceding generations of machine learning (ML), DL approaches based on convolutional neural networks (CNNs) can deal with raw intensity images and acquire to extract analytical features automatically. This study uses multimodal imaging to propose an Artificial Intelligence with Deep Convolutional Neural Network Based Clinical Decision Making on Kidney Oncology (AIDCNN-CDMKO) methodology. The primary purpose of the AIDCNN-CDMKO methodology framework is to support clinical decision-making for the precise identification and classification of kidney tumours. The presented AIDCNN-CDMKO methodology initially utilizes the Gaussian filter (GF) in the image pre-processing to enhance image clarity by reducing noise and improving feature detectability. Furthermore, the fusion of feature extraction models such as VGG16, MobileNetV1, and EfficientNetB5 is employed to capture rich and complementary representations from multimodal imaging data. The attention mechanism-based CNN and bi-directional long short-term memory (CNN-BiLSTM-AM) classifier is utilized for kidney cancer detection. To validate the improved analytical results of the AIDCNN-CDMKO approach, extensive simulations are conducted under the CT Kidney and RCC Kidney Histopathology datasets. The comparative study of the AIDCNN-CDMKO exemplified a superior accuracy value of 98.33% and 98.42% under the dual datasets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.